Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients
Phase 4
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: NAABAK eyedropsDrug: Saline eyedrops
- Registration Number
- NCT01203540
- Lead Sponsor
- Laboratoires Thea
- Brief Summary
Multicentre, Double blind, Randomized, Comparative Study(comparing N-acetyl-aspartyl-glutamic acid(NAAGA) in Abak preservative free device versus SALINE in Abak preservative free device.
Evaluation of the effects and safety of NAABAK® through inflammation markers and symptoms in patients with allergic conjunctivitis and dry eye syndrome after 3 months treatment.
The patients will attend 4 visits.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
- Age ≥ 20 years old
- Patients with dry eye syndrome in allergic conjunctivitis
Exclusion Criteria
- Severe dry eye syndrome
- Severe ocular pathology
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Naaga in ABAK system NAABAK eyedrops - Saline solution Saline eyedrops -
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Korea, Republic of
Seoul National University Boramae Medical Center
🇰🇷Seoul, Korea, Republic of